ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "infliximab"

  • Abstract Number: 1551 • 2014 ACR/ARHP Annual Meeting

    Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction

    Denis Choquette1, Carter Thorne2, Majed Khraishi3, Isabelle Fortin4, Regan Arendse5, Andrew Chow6, John Kelsall7, Milton Baker8, Julie Vaillancourt9, John S. Sampalis9, Francois Nantel10, Allen J Lehman11, Susan Otawa11 and May Shawi10, 1Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, 2Southlake Regional Health Centre, Newmarket, ON, Canada, 3Nexus Clinical Research, St John's, NF, Canada, 4Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 5University of Saskatchewan, Saskatoon, SK, Canada, 6University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 7The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 8University of Victoria, Victoria, BC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose The Health Assessment Questionnaire (HAQ) is commonly used for assessing patient-reported functional status and disease activity in psoriatic arthritis (PsA). However, it has been…
  • Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting

    Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population

    Boulos Haraoui1, Algis Jovaisas2, William G. Bensen3, Rafat Faraawi4, John Kelsall5, Sanjay Dixit4, Jude Rodrigues6, Maqbool Sheriff7, Emmanouil Rampakakis8, John S. Sampalis8, Allen J Lehman9, Susan Otawa9, Francois Nantel10 and May Shawi10, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, 4McMaster University, Hamilton, ON, Canada, 5The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 6Clinical Research and Arthritis Centre, Windsor, ON, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8JSS Medical Research, Montreal, QC, Canada, 9Medical Affairs, Janssen Inc., Toronto, ON, Canada, 10Janssen Inc., Toronto, ON, Canada

    Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
  • Abstract Number: 402 • 2014 ACR/ARHP Annual Meeting

    Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis?

    Masao Sato1,2, Masao Takemura2,3, Kuniaki Saito4 and Yasuko Yamamoto4, 1Rheumatology, Matsunami General Hospital, Gifu, Japan, 2Matsunami Reserch Park, Gifu, Japan, 3Informative Laboratory Merdicine, Gifu University, Gifu, Japan, 4Human Health Science, Kyoto University, Kyoto, Japan

    Background/Purpose GP88 (progranulin; PGRN), a glycoprotein with a molecular weight of approximately 88000, is suggested to play an important role in the immune response and…
  • Abstract Number: 365 • 2014 ACR/ARHP Annual Meeting

    Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada

    Denis Choquette1, Dalton Sholter2, Isabelle Fortin3, Michael Starr4, Carter Thorne5, Milton Baker6, Regan Arendse7, Philip Baer8, Michel Zummer9, Jude Rodrigues10, Maqbool Sheriff11, Emmanouil Rampakakis12, John S. Sampalis12, Francois Nantel13, Allen J Lehman14, Susan Otawa14 and May Shawi13, 1Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, 2University of Alberta, Edmonton, AB, Canada, 3Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 4Montreal General Hospital, Montreal, QC, Canada, 5Southlake Regional Health Centre, Newmarket, ON, Canada, 6University of Victoria, Victoria, BC, Canada, 7University of Saskatchewan, Saskatoon, SK, Canada, 8Private Practice, Scarborough, ON, Canada, 9Université de Montréal, Montreal, QC, Canada, 10Clinical Research and Arthritis Centre, Windsor, ON, Canada, 11Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 12JSS Medical Research, Montreal, QC, Canada, 13Janssen Inc., Toronto, ON, Canada, 14Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose DAS28 is an important outcome for clinical research and practice assisting with therapeutic decisions. The main contributors to DAS28 are joint tenderness and acute-phase…
  • Abstract Number: 248 • 2014 ACR/ARHP Annual Meeting

    Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?

    Proton Rahman1, Algis Jovaisas2, William Bensen3, Wojciech Olszynski4, Anna Jaroszynska5, Philip Baer6, Maqbool Sheriff7, Dalton Sholter8, Eliofotisti Psaradellis9, John S. Sampalis9, Francois Nantel10, Allen J Lehman11, Susan Otawa11 and May Shawi10, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2194 Main Street, University of Ottawa, Ottawa, ON, Canada, 3Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 4University of Saskatchewan, Saskatoon, SK, Canada, 5Private Practice, Burlington, ON, Canada, 6Private Practice, Scarborough, ON, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8University of Alberta, Edmonton, AB, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose The present standard for measuring disease activity in AS is the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses on five major symptoms…
  • Abstract Number: L14 • 2014 ACR/ARHP Annual Meeting

    Determination of Efficacy of Intra-Articular Infliximab Therapy in JIA Patients By 3D/4D Musculo-Skeletal Ultrasound

    Miroslav Harjacek1, Mandica Vidovic2, Lovro Lamot2,3, Marija Perica2 and Lana Tambic Bukovac2, 1Rheumatology, Children's Hospital Srebrnjak, Zagreb, Croatia, 2Children's Hospital Srebrnjak, Zagreb, Croatia, 3University of Zagreb School of Medicine, Zagreb, Croatia

    Background/Purpose: Intra-articular (IA) infliximab (IFX) is an attractive treatment option of chronic arthritis, but based on few heterogenic studies, outcome is still controversial. To investigate…
  • Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting

    Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio

    Bente Glintborg1,2, Bjorn Gudbjornsson3,4, Niels Steen Krogh5, Emina Omerovic2, Natalia Manilo6, Mette Holland-Fischer7, Hanne M. Lindegaard8, Anne Gitte Loft9, Henrik Nordin10, Laura Johnsen11, Sussi Flejsborg Oeftiger12, Annette Hansen13, Claus Rasmussen14, Gerdur Grondal15, Árni Jón Geirsson16 and Merete Lund Hetland1,2,17, 1The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 3Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, 4Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 5ZiteLab ApS, Copenhagen, Denmark, 6Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, 7Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 8Department of Rheumatology, Odense University Hospital, Odense, Denmark, 9Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, 10Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, 11Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Denmark, 12Department of Rheumatology, Køge Hospital, Køge, East Timor, 13Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, 14Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, 15Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, 16Rheumatology, Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, 17Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark

    Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…
  • Abstract Number: 2458 • 2013 ACR/ARHP Annual Meeting

    Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care

    Denis Choquette1, Michael Starr2, Majed M. Khraishi3, William G. Bensen4, Saeed A. Shaikh5, Jude F. Rodrigues6, Dalton E. Sholter7, Maqbool K. Sheriff8, Julie Vaillancourt9, John S. Sampalis9, Allen J. Lehman10, Susan M. Otawa10, Francois Nantel11 and May Shawi12, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Montreal General Hospital, Montreal, QC, Canada, 3Nexus Clinical Research, St John's, NF, Canada, 4Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 5Medicine, McMaster University, St Catharines, ON, Canada, 6Rheumatology, Windsor, ON, Canada, 7Rheumatology Associates, Edmonton, AB, Canada, 8Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Medical Affairs, Janssen Inc., Toronto, ON, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: Canadian provincial reimbursement policies in regards with infliximab coverage status have evolved in the last decade. The objective of this study was to describe…
  • Abstract Number: 2369 • 2013 ACR/ARHP Annual Meeting

    Long-Term Outcome Of Infliximab Therapy In Rheumatoid Arthritis Patients: Results From Japanese Multicenter Registry System

    Nobunori Takahashi1, Toshihisa Kojima2, Atsushi Kaneko3, Yuji Hirano4 and Naoki Ishiguro1, 1Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, 3Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, 4Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan

    Background/Purpose: After demonstration of effectiveness of anti-tumor necrosis factor (TNF) agents in patients with rheumatoid arthritis (RA), their use has become common practice in treating…
  • Abstract Number: 2320 • 2013 ACR/ARHP Annual Meeting

    Ultrasonographic Monitoring Of Response To Infliximab In Patients With Rheumatoid Arthritis

    Xiaomei Leng1, Weiguo Xiao2, Xiaochun Zhu3, Zhonghui Xu1, Wei Yu1, Jing Lu2, Jiakai Wang2, Xiaoru Xia3, Yongji Li3, Yi Liu4, Yi Zhao4, Honghao Tang5, Dongbao Zhao6, Yeqing Shi6, Huji Xu7, Jun Bao7, Lin Chen7, Ling Lin7, Ling Zhou7, Guoqiang Chen8, Weihong Zhang8 and Yan Zhao1, 1Peking Union Medical College Hospital, Beijing, China, 2The First Hospital of China Medical University, Shenyang, China, 3The First Hospital of Wenzhou Medical College, Wenzhou, China, 4Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, 5West China Hospital of Sichuan University, Chengdu, China, 6Changhai Hospital of Shanghai, Shanghai, China, 7Shanghai Changzheng Hospital, Shanghai, China, 8The First People’s Hospital of Foshan, Foshan, China

     Background/Purpose: To evaluate the efficacy of treatment with infliximab on joint inflammation and bone erosion in rheumatoid arthritis (RA) patients using ultrasonography. Methods: 80 eligible…
  • Abstract Number: 2223 • 2013 ACR/ARHP Annual Meeting

    Monitoring Of Active Matrix Metalloproteinase-3 Using

    Sung Jae Choi1, Young Ho Seo2, Young Ho Lee3, Jong Dae Ji1, Gwan Gyu Song4, Aeju Lee2 and Jae-Hoon Kim4, 1Rheumatology, Korea University Medical Center, Seoul, South Korea, 2Rheumatology, Korea University Medical center, Seoul, South Korea, 3Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, 4Div of Rheum, Dept of Int Med, Korea Univ College of Med, Seoul, South Korea

    Background/Purpose: Active matrix metalloproteinase-3 (MMP-3) is a prognostic marker of rheumatoid arthritis (RA). Recently, we developed the MMP-3 probe which can specifically detect an active…
  • Abstract Number: 1554 • 2013 ACR/ARHP Annual Meeting

    Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience

    Proton Rahman1, Majed M. Khraishi2, William Bensen3, John T. Kelsall4, Brian D. Hanna5, Craig Watts6, Emmanouil Rampakakis7, John S. Sampalis7, May Shawi8, Susan M. Otawa9 and Allen J. Lehman9, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Nexus Clinical Research, St John's, NF, Canada, 3St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, 4Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 5Rheumatology, McMaster University, Ontario, Kitchener, ON, Canada, 6Department of Rheumatology, McGill University and Montreal General Hospital, Sainte-Anne-de-Bellevue, QC, Canada, 7JSS Medical Research, Montreal, QC, Canada, 8Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, 9Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…
  • Abstract Number: 532 • 2013 ACR/ARHP Annual Meeting

    Role Of Baseline C-Reactive Protein In Response To Infliximab Plus Naproxen Vs Naproxen Alone In Patients With Axial Spondyloarthritis

    J Sieper1, M Rudwaleit1, J Lenaerts2, J Wollenhaupt3, L Myasoutova4, S Park5, Y Song6, R Yao7, M Govoni8, D Chitkara9 and N Vastesaeger10, 1University Clinic Benjamin Franklin, Berlin, Germany, 2Practice Rheumatology, Hasselt, Belgium, 3Schön-Klinik, Hamburg, Germany, 4Kazan State Medical University, Kazan, Russia, 5Catholic University of Korea, Seoul, South Korea, 6Seoul National University, Seoul, South Korea, 7Merck & Co., Inc., Whitehouse Station, NJ, 8MSD Italy, Rome, Italy, 9Merck Sharp & Dohme, Kenilworth, NJ, 10Merck Sharp & Dohme, Brussels, Belgium

    Background/Purpose: Baseline inflammation has been shown to influence response to tumor necrosis factor alpha antagonist treatment in patients with axial spondyloarthritis (SpA). This study evaluated…
  • Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting

    Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry

    Denis Choquette1, J. Carter Thorne2, John T. Kelsall3, Michel Zummer4, Michael Starr5, Maqbool K. Sheriff6, William G. Bensen7, Andrew Chow8, Philip Baer9, Emmanouil Rampakakis10, John S. Sampalis10, Francois Nantel11, Allen J. Lehman12, Susan M. Otawa12 and May Shawi13, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Southlake Regional Health Centre, Newmarket, ON, Canada, 3Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 4Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, 5Montreal General Hospital, Montreal, QC, Canada, 6Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 7Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 8University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 9Private Practice, Scarborough, ON, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada, 13Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…
  • Abstract Number: 499 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial

    Robin Christensen1, Simon Tarp1, Daniel Furst2, Lars E. Kristensen3 and Henning Bliddal4, 1Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 2David Geffen School of Medicine, University of California, Los Angeles, CA, 3Rheumatology, Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, 4Department of Rheumatology, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark

    Background/Purpose: Using combined data from the ATTEST [1] and AMPLE [2] study comparing infliximab and adalimumab with abatacept in patients with rheumatoid arthritis (RA), we…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology